Research Topics
Genomes and GenesSpecies | Clemens Martin WendtnerSummaryAffiliation: University of Munich Country: Germany Publications
| Collaborators
|
Detail Information
Publications
Treatment of primary, recurrent or inadequately resected high-risk soft-tissue sarcomas (STS) of adults: results of a phase II pilot study (RHT-95) of neoadjuvant chemotherapy combined with regional hyperthermiaC Wendtner
Department of Internal Medicine III, Klinikum Grosshadern Medical Center KGMC, Ludwig Maximilians University, D 81377, Munich, Germany
Eur J Cancer 37:1609-16. 2001..027), but this did not affect DMFS (P=0.558) or OS (P=0.126). Hence, postsurgical thermochemotherapy seems critical for local tumour control without affecting survival...- Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomasClemens M Wendtner
Department of Internal Medicine III, Diagnostic Radiology and Institute for Biostatistics and Epidemiology, Klinikum Grosshadern Medical Center, Ludwig Maximilians University, Munich, Germany
J Clin Oncol 20:3156-64. 2002.... - High level of transgene expression in primary chronic lymphocytic leukemia cells using helper-virus-free recombinant Epstein-Barr virus vectorsClemens Martin Wendtner
Medical Clinic III, University Hospital Grosshadern, Ludwig Maximilians University, Marchioninistrasse 15, D 81377 Munich, Germany
Exp Hematol 31:99-108. 2003..Recombinant EBV was explored for transduction of primary human B-cell chronic lymphocytic leukemia (CLL) cells... - The potential of gene transfer into primary B-CLL cells using recombinant virus vectorsC M Wendtner
Medical Clinic III, Klinikum Grosshadern Medical Center, Munchen, German
Leuk Lymphoma 45:897-904. 2004..This will make it possible to establish the potential clinical role of gene therapy for CLL patients... 
Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre studyRolf D Issels
Klinikum der Universität München Campus Grosshadern, Munchen, Germany
Lancet Oncol 11:561-70. 2010..We designed a parallel-group randomised controlled trial to assess the safety and efficacy of regional hyperthermia with chemotherapy...- Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytesChristine Mayr
Klinische Kooperationsgruppe Gene Therapy, Munich, Germany
Blood 105:1566-73. 2005..In summary, FMOD was shown for the first time to be naturally processed and presented as TAA in primary CLL cells, enabling the expansion of autologous tumor-specific T cells... - Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomasMarcus Schlemmer
Department of Internal Medicine III, Klinikum Grosshadern Medical Center, Munich, Germany
Oncology 71:32-9. 2006..We report phase II data of high-dose chemotherapy and peripheral blood stem cell (PBSC) rescue in patients with MSTS responding to AI-G chemotherapy... - Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cellsChristine Mayr
KKG Gene Therapy, GSF National Research Center for Environment and Health, Munich, Germany
Blood 106:3223-6. 2005..001). Thus, CD40L-transduced CLL cells are able to induce an antigen-specific T-cell response and might be superior to CD40-CLL cells for immune-based therapeutic strategies in CLL... 
Evaluation of the proposed reporting system of the European LeukemiaNet and recommendations for prognosis of acute myeloid leukemiaTamara Alpermann
MLL Munich Leukemia Laboratory, Munich, Germany
Leuk Res 37:197-200. 2013..5), and adverse (adverse cytogenetics). Significant differences in outcomes between all four subgroups were found...- A novel hierarchical prognostic model of AML solely based on molecular mutationsVera Grossmann
MLL Munich Leukemia Laboratory, Munich, Germany
Blood 120:2963-72. 2012..9%); and (5) very unfavorable: TP53 mutation (n = 80; OS at 3 years: 0%; P < .001). This comprehensive molecular characterization provides a more powerful model for prognostication than cytogenetics... - CD23 is recognized as tumor-associated antigen (TAA) in B-CLL by CD8+ autologous T lymphocytesDagmar Bund
KKG Gene Therapy, GSF National Research Center for Environment and Health, Munich, Germany
Exp Hematol 35:920-30. 2007..CD23 is constitutively and atypically expressed on malignant B cells in patients with chronic lymphocytic leukemia (B-CLL). Here, we investigated whether CD23-derived peptides might function as B-CLL-specific tumor-associated antigen (TAA)... - Enhancement of gene transfer with recombinant adeno-associated virus (rAAV) vectors into primary B-cell chronic lymphocytic leukemia cells by CpG-oligodeoxynucleotidesHans D Theiss
KKG Gene Therapy, GSF-National Research Center for Environment and Health, Munich, Germany
Exp Hematol 31:1223-9. 2003..30). CONCLUSION: Stimulation by CD40L is crucial for efficient gene transfer into B-CLL cells by rAAV vectors, whereas transduction efficiency can be significantly enhanced by CpG-ODNs... - Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectorsClemens-Martin Wendtner
Medical Clinic III, University Hospital Grosshadern and Gene Center, Ludwig-Maximilians-University, Munich, Germany
Blood 100:1655-61. 2002..Vaccination strategies for patients with B-CLL using leukemia cells infected ex vivo by rAAV vectors now seems possible in the near future... - Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemiaChristine Mayr
, Munich, Germany
Blood 107:742-51. 2006..Our data may facilitate the identification of molecular events crucial for transforming activity in this disease and should have implications for risk-adapted clinical management of patients with CLL... - MDM2 is recognized as a tumor-associated antigen in chronic lymphocytic leukemia by CD8+ autologous T lymphocytesChristine Mayr
KKG Gene Therapy, GSF-National Research Center for Environment and Health, Munich, Germany
Exp Hematol 34:44-53. 2006..MDM2 was demonstrated to be naturally processed and presented as TAA in primary human CLL cells enabling expansion of functional autologous tumor-specific T cells...